ArticleFrontiers in molecular biosciences2020
CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer.
Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.PLoS computational biology · 2026Article
- Article
- Comparative Transcriptomics Study of Curcumin and Conventional Therapies in Translocation, Clear Cell, and Papillary Renal Cell Carcinoma Subtypes.International journal of molecular sciences · 2025Article
- The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025Review
- Protumor effect of CXCL10/CXCR3 axis in canine mammary gland tumor.Journal of veterinary science · 2025Article
- The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells.Antioxidants (Basel, Switzerland) · 2024Article
- The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.Cellular & molecular biology letters · 2024Review
- Article
- A novel prognostic signature of chemokines for survival and immune infiltration in kidney renal clear cell carcinoma.International journal of medical sciences · 2023Article
- Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes.Journal of cellular and molecular medicine · 2023Article
- Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.BMC medical genomics · 2022Article
- Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.International journal of molecular sciences · 2022Article
- The role of CXCR3 and its ligands in cancer.Frontiers in oncology · 2022Review
- Bioinformatics, Molecular Docking and ExperimentsFrontiers in oncology · 2021Article
- IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the effects of the CXC chemokine/receptor axis on lymph node and distant metastases of prostate cancer (PC) were analyzed. Further, mRNA expression data of metastatic PC were extracted from the Stand Up To Cancer-Prostate Cancer Foundation Dream Team database and differences between metastatic sites were comprehensively analyzed. CXC chemokine/receptor mRNA expression data of primary PC included in the Cancer Genome Atlas were used to analyze the relationships of CXC chemokine/receptor expression with lymph node metastasis and cancer progression. In metastatic PC, significantly higher expression of ELR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.